Drug Class Detail

Drug Class HSP90 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SH-1242 HSP90 Inhibitor 35 SH-1242 is an analog of deguelin that binds the C-terminus of Hsp90 and inhibits its function, resulting in decreased tumor cell growth (PMID: 26645561).
PF-4942847 HSP90 Inhibitor 35 PF-4942847 inhibits HSP90, resulting in the degradation of HSP90 client proteins, which may lead to decreased proliferation and increased apoptosis of tumor cells (PMID: 21715568).
Alvespimycin KOS-1022|17-DMAG HSP90 Inhibitor 35 Alvespimycin is a small molecule inhibitor of HSP90, which potentially leads to decreased tumor growth (PMID: 15791458).
Retaspimycin IPI-504 HSP90 Inhibitor 35 Retaspimycin (IPI-504) inhibits HSP90, potentially resulting in increased tumor cell apoptosis (NCI Drug Dictionary).
IPI-493 17-AG HSP90 Inhibitor 35 IPI-493 inhibits HSP90, which may result in increased apoptosis and decreased tumor growth (PMID: 21737509).
BIIB021 HSP90 Inhibitor 35 BIIB021 is a synthetic HSP90 inhibitor, which may lead to increased tumor cell death and decreased tumor growth (PMID: 19372565).
Triolimus Antimicrotubule Agent 11 HSP90 Inhibitor 35 mTORC1 Inhibitor 8 Triolimus is a composed of a micelle containing the drugs rapamycin, 17-AAG, and paclitaxel, which act synergistically to inhibit tumor growth (PMID: 22896668).
SNX-5422 PF-04929113 HSP90 Inhibitor 35 SNX-5422 is the prodrug of the potent Hsp90 inhibitor SNX-2112, which has been shown to decrease activation Her-2, Akt, and ERK, inhibit tumor cell proliferation, and induce tumor cell apoptosis (PMID: 21349995, PMID: 18948577).
NMS-E973 HSP90 Inhibitor 35 NMS-E973 binds to and inhibits HSP90, resulting in decreased tumor cell proliferation (PMID: 23674492).
CPUY201112 HSP90 Inhibitor 35 CPUY201112 is an N-terminal Hsp90 inhibitor, which leads to decreased expression of Hsp90 client proteins and may result in increased tumor cell apoptosis (PMID: 26743233).
TAS-116 HSP90 Inhibitor 35 TAS-116 is a selective inhibitor of HSP90-alpha and HSP90-beta, which may lead to decreased tumor growth (PMID: 25416789).
SNX-7081 HSP90 Inhibitor 35 SNX-7081 inhibits Hsp90, resulting in increased cell cycle arrest and apoptosis of tumor cells (PMID: 20738310).
STA-8666 PEN-866|STA-12-8666 HSP90 Inhibitor 35 STA-8666 is a molecule that targets active HSP90 and is linked to the active metabolite of Camptosar (irinotecan), SN38, which may result in antitumor activity including tumor stabilization and regression (PMID: 27267850).
Tanespimycin 17-AAG HSP90 Inhibitor 35 Tanespimycin (17-AAG) is a HSP90 inhibitor, potentially leading to decreased tumor growth (PMID: 19601813).
SST0116CL1 HSP90 Inhibitor 35 SST0116CL1 is a second-generation small molecule inhibitor of Hsp90, which leads to decreased expression of Hsp90 client proteins and reduced tumor cell proliferation and tumor growth (PMID: 25096516).
PF4942847 HSP90 Inhibitor 35 PF4942847 is a HSP90 inhibitor that affects oncogenic protein maturation and stability, leading to growth inhibition in tumor cells (PMID: 26712686).
Onalespib AT13387 HSP90 Inhibitor 35 Onalespib (AT13387) inhibits Hsp90, which may result in decreased tumor growth (PMID: 22181674, PMID: 22714264).
NXD30001 HSP90 Inhibitor 35 NXD30001 inhibits HSP90, potentially resulting in decreased tumor growth (PMID: 23714726, PMID: 20643786).
CH5138303 HSP90 Inhibitor 35 CH5138303 is a small molecule inhibitor of HSP90, which may lead to decreased tumor growth (PMID: 24369839).
PU-H71 NSC 750424 HSP90 Inhibitor 35 PU-H71 selectively inhibits Heat shock protein 90 (Hsp90), resulting in increased proteosomal degradation of oncogenic client proteins and potentially leading to decreased tumor growth (PMID: 28808818).
MPC-3100 HSP90 Inhibitor 35 MPC-3100 is a synthetic HSP90 inhibitor, which may lead to decreased tumor cell growth and survival (NCI Drug Dictionary).
Debio 0932 CUDC-305 HSP90 Inhibitor 35 Debio0932 is a second-generation Hsp90 inhibitor, which may decrease tumor cell proliferation and increase sensitivity to cytotoxic agents (Cancer Res August 1, 2015 75; 683).
Novobiocin Albamix Antibiotic Pa-93 HSP90 Inhibitor 35 Novobiocin binds to and inhibits HSP90, resulting in degradation of HSP90 client proteins (PMID: 10945979).
XL888 HSP90 Inhibitor 35 XL888 inhibits HSP90, resulting in degradation of HSP90 client proteins, and potentially leading to decreased tumor growth (PMID: 23538902, PMID: 22877636).
Luminespib AUY922|NVP-AUY922 HSP90 Inhibitor 35 Luminespib (AUY922) inhibits HSP90, resulting in increased tumor cell apoptosis and decreased tumor cell angiogenesis and proliferation (PMID: 25955495, PMID: 18413753).
C086 BCR-ABL Inhibitor 23 HSP90 Inhibitor 35 C086 inhibits HSP90 and BCR-ABL, resulting in decreased proliferation of tumor cells, including imatinib-resistant cells (PMID: 25501124).
Panvotinib-401 HSP90 Inhibitor 35 Panvotinib-401 is a small molecule Hsp90 inhibitor that is mitochondrial inner membrane-permeable, resulting in cancer cell toxicity (AACR, Cancer Res: April 2016; Volume 57, Abstract #3896).
HSP990 NVP-HSP990 HSP90 Inhibitor 35 HSP990 inhibits HSP90, which may lead to decreased tumor growth (PMID: 22246440).
Geldanamycin HSP90 Inhibitor 35 Geldanamycin binds to and inhibits HSP90, potentially resulting in decreased tumor cell growth and increased tumor cell apoptosis (PMID: 19850405, PMID: 11927289).
Ganetespib STA-9090 HSP90 Inhibitor 35 Ganetespib is a small molecule that inhibits Hsp90, resulting in the degradation and inactivation of Hsp90 client proteins and decreased cell proliferation (NCI Drug Dictionary).
WK88-1 HSP90 Inhibitor 35 WK88-1 inhibits HSP90, resulting in decreased expression of HSP90 client proteins and potentially leading to decreased tumor cell growth (PMID: 25117641).
KW-2478 HSP90 Inhibitor 35 KW-2478 inhibits HSP90, which may result in increased apoptosis and decreased growth of tumor cells (PMID: 20406843).
DS-2248 HSP90 Inhibitor 35 DS-2248 inhibits Heat Shock Protein 90, potentially resulting in decreased proliferation of tumor cells (NCI Drug Dictionary).
SNX-2112 PF-04928473 HSP90 Inhibitor 35 SNX-2112 (PF-04928473) inhibits HSP90, resulting in increased apoptosis and decreased tumor cell growth (PMID: 21821931, PMID: 22447251).
17-Demethoxy-reblastatin 17-DR HSP90 Inhibitor 35 17-demethoxy-reblastatin is a second generation HSP90 inhibitor, which may lead to decreased proliferation and increased apoptosis of tumor cells (PMID: 26323360).
Molecular Profile Protein Effect Treatment Approaches